Vilma Graupner

1.1k citations
8 papers · 725 · 1 hit paper · h-index 6

Impact in

  • Oncology top 5%
    • Cancer Immunotherapy and Biomarkers
    • Lung Cancer Research Studies
    • Pancreatic and Hepatic Oncology Research
    • CAR-T cell therapy research
    • Lung Cancer Treatments and Mutations
    • Lung Cancer Diagnosis and Treatment

Papers in

    • Cancer Immunotherapy and Biomarkers 7
    • CAR-T cell therapy research 4
    • Lung Cancer Research Studies 3
    • HER2/EGFR in Cancer Research 2
    • Peptidase Inhibition and Analysis 1
    • Lung Cancer Treatments and Mutations 2

Vilma Graupner

8 papers receiving 720 citations

Vilma Graupner's Hit Papers

Atezolizumab in Combination With Carboplatin and Nab-Paclitaxel in Advanced Squamous NSCLC (IMpower131): Results From a Randomized Phase III Trial 2020 · 405 citations
4050+2+4Years since publication100200300400

Peers

Vilma Graupner
Comparison fields: 5 of 46
  • Oncology 680
  • Pulmonary and Respiratory Medicine 484
  • Immunology 134
  • Cancer Research 63
  • Radiology, Nuclear Medicine and Imaging 39
Replace Shawn W. Sun with:
Shawn W. Sun United States
Junliang Cai United States
Jorge Alatorre-Alexander Mexico
Osvaldo Arén Frontera United States
Balazs Medgyasszay Spain
Iveta Kudaba Latvia
M-J. Ahn South Korea
A. Sandler United States
Prabhu Bhagavatheeswaran United States
Virginia Palomar Coloma France
Vilma Graupner relative to Shawn W. Sun United States Shawn W. Sun's profile →
Citations per field
00.5×1.5×
Shawn W. Sun · 1×
Citations per year

Countries citing papers authored by Vilma Graupner

Since Specialization
Citations

This map shows the geographic impact of Vilma Graupner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Vilma Graupner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Vilma Graupner more than expected).

Fields of papers citing papers by Vilma Graupner

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Vilma Graupner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Vilma Graupner. The network helps show where Vilma Graupner may publish in the future.

Co-authors

The 25 scholars most cited alongside Vilma Graupner, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Vilma Graupner Line = papers co-authored together Vilma Graupner links everyone, so they are left out of the graph.

All Works

8 of 8 papers shown
#Work
1
Atezolizumab in Combination With Carboplatin and Nab-Paclitaxel in Advanced Squamous NSCLC (IMpower131): Results From a Randomized Phase III Trial
Hit paper breakdown →
2020405
2 2018170
3 202282
4 201823
5 202123
6 201915
7 20225
8 20252

About Vilma Graupner

Vilma Graupner is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Immunology, Molecular Biology and Radiology, Nuclear Medicine and Imaging, having authored 8 papers that have together received 725 indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (7 papers), CAR-T cell therapy research (4 papers), Lung Cancer Research Studies (3 papers), Lung Cancer Treatments and Mutations (2 papers), Immunotherapy and Immune Responses (2 papers), HER2/EGFR in Cancer Research (2 papers), Peptidase Inhibition and Analysis (1 paper) and Breast Cancer Treatment Studies (1 paper). The work is most often cited by research in Oncology (680 citations), Pulmonary and Respiratory Medicine (484 citations), Immunology (134 citations), Cancer Research (63 citations) and Radiology, Nuclear Medicine and Imaging (39 citations). Vilma Graupner has collaborated with scholars based in Switzerland, United States and Japan. Frequent co-authors include Toshiyuki Kozuki, Tien Hoang, Ross A. Soo, Mark A. Socinski, Robert M. Jotte, Daniil Stroyakovskiy, Henry Jacob Conter, Federico Cappuzzo, Ihor Vynnychenko and Maen Hussein. Their work appears in journals such as Journal of Clinical Oncology, Journal of Thoracic Oncology, Annals of Oncology and The Journal of Clinical Pharmacology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact